NuvOx Pharma will target a USD 15m Series A raise in 2014 for its glioblastoma multiforme (GBM) candidate, NVX108,
according to Chief Business Officer David Wilson. (Source: BioPharm Insight) Continue reading
NuvOx Pharma will target a USD 15m Series A raise in 2014 for its glioblastoma multiforme (GBM) candidate, NVX108,
according to Chief Business Officer David Wilson. (Source: BioPharm Insight) Continue reading→